drug_type
RELEVANT_DRUG
intervention_type
Biological (monoclonal antibody)
drug_description
Chimeric IgG1 monoclonal antibody TNF-α inhibitor administered subcutaneously (120 mg every 2 weeks). Binds soluble and transmembrane TNF-α, preventing TNFR1/2 engagement, suppressing NF-κB signaling and downstream pro-inflammatory mediators; can mediate ADCC/CDC against TNF-expressing cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Infliximab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Chimeric IgG1 monoclonal antibody that binds soluble and transmembrane TNF-α, blocking TNFR1/2 engagement and downstream NF-κB signaling to suppress pro‑inflammatory mediators; can also mediate ADCC/CDC against TNF‑expressing cells.
drug_name
Infliximab (CT-P13 SC; Remsima)
nct_id_drug_ref
NCT05424926